Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PANK3 | Q9H999 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 16/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 16/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24323519 | 0.86 | PANK3 (0.41) | PANK3OPRM1OPRL1EGLN2PARP1 | |
| SCHEMBL24323948 | 0.82 | PANK3 (0.42) | PANK3OPRM1OPRL1EGLN2PARP1 | |
| SCHEMBL28024107 | 0.78 | PANK3 (0.49) | PANK3EGLN2PARP1 | |
| SCHEMBL153675 | 0.75 | ALDH1A1 (0.48) | PANK3PARP1 | |
| SCHEMBL151146 | 0.74 | PANK3 (0.47) | PANK3PARP1 | |
| SCHEMBL150176 | 0.73 | ALDH1A1 (0.47) | PANK3PARP1 | |
| SCHEMBL139436 | 0.73 | ALDH1A1 (0.47) | PANK3PARP1 | |
| SCHEMBL24323937 | 0.70 | TDP1 (0.30) | — | |
| SCHEMBL154604 | 0.70 | KDM4E (0.47) | PANK3 | |
| SCHEMBL24989603 | 0.70 | CHRNB2 (0.50) | PANK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150377-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2024-05-09 | — | — | US | disclosed |
| EP-4225765-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| CN-116601158-A | Modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2023-08-15 | — | — | CN | disclosed |
| WO-2022076622-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022076622-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150377-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | PANK3 1521/4885OPRM1 1198/4885OPRL1 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.